Tempus AI TEM, an innovator in artificial intelligence-based healthcare solutions, has been attracting investors' interest ...

In the assessment of 12-month price targets, analysts unveil insights for Tempus AI, presenting an average target of $64.09, ...

The Chicago-based Tempus spinout called the financing round a major milestone as it expands its AI-enabled platform.

Pathos AI has raised $365m in a Series D funding round as it prepares to widen its AI-enabled platform to advance the ...

Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised ...

The prize is better outcomes, but the price may be sharing more personal details. Lawyers are working on the new rules ...

A technology company specializing in the application of artificial intelligence to advance precision medicine and patient ...

Following after is P-500, a selective, brain-penetrant PRMT5 inhibitor for advanced solid tumours, including high-grade ...

NEAR Protocol just released something pretty amazing - version 3 of the NEAR PoA - which has a block time of 1s. To give you ...

Pathos AI, a US biotech specializing in artificial intelligence for cancer drug development, has raised $365 million in a ...

Get our top picks of the posters at AACR 2025 and learn more about the method behind them and the techniques used.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...